Vinay Sundaram
Hepatology · Los Angeles, CANPI 1316169402
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $133,950 of the $202,533 with a category attached, or 66.1%. 16 manufacturers reported payments, led by Gilead at 34.8% of the total. Reporting peaked in 2019 at $94,191 and has fallen 84.1% since, to $15,000 in 2024.
Across 260 payments — averaging $778.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$70K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$56K
- AbbVie$34K
- BD$11K
- Dova Pharmaceuticals$10K
- Intercept Pharmaceuticals, Inc.$9K
- plus $12K from 10 others
Across 83 payments — averaging $6308.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Intercept Pharmaceuticals, Inc.$386K
- Grifols Therapeutics LLC$122K
- Dova Pharmaceuticals$8K
- Bausch Health US, LLC$6K
- Grifols Biologicals LLC$2K
What the payments were for
- Consulting fees$18,4609%
- Speaking & faculty fees$133,95066%
- Grants$30,00015%
- Travel & lodging$13,8347%
- Food & beverage$6,2693%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 101 | $70,472 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 53 | $56,466 |
| AbbVie | 50 | $33,530 |
| BD | 7 | $10,609 |
| Dova Pharmaceuticals | 9 | $9,764 |
| Intercept Pharmaceuticals, Inc. | 13 | $9,311 |
| Saol International Limited | 6 | $4,400 |
| Shionogi Inc | 9 | $4,192 |
| Saol Therapeutics Inc. | 2 | $3,305 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $245 |
| Mallinckrodt Enterprises LLC | 2 | $55 |
| Mallinckrodt Hospital Products Inc. | 2 | $54 |
| Novo Nordisk | 2 | $51 |
| Ultragenyx Pharmaceutical Inc. | 1 | $32 |
| Echosens North America, Inc. | 1 | $32 |
| Novartis | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$202,533 in reported general payments places this provider in the 85th percentile of 36 hepatology providers in California.
Other hepatology in Los Angeles
- Sergio RojterLos Angeles$58K
- Mohamed El KabanyLos Angeles$4K
- Amandeep SahotaLos Angeles$31
- Victor WuLos Angeles$19
- Robert GishFolsom$1.9M
- Edward MenaPasadena$624K
- Walid AyoubWest Hollywood$416K
- Tarek HassaneinCoronado$278K
- Ke-Qin HuOrange$239K
- Marina RoytmanFresno$165K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.